Chikungunya IgM ELISA Kit (DEIA2163)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum, plasma
Species Reactivity
Human
Intended Use
The Chikungunya IgM-μ-capture ELISA is intended for measurement of IgM class antibodies to Chikungunya virus in human serum and plasma (citrate).
Contents of Kit
1. Chikungunya Microplate (IgM): 12 breakapart 8-well snap-off strips coated with anti human IgM, in resealable aluminium foil.
2. Sample Diluent ***: 1 bottle containing 100 mL of ready to use buffer for sample dilution; pH 7.2 ± 0.2; coloured yellow; white cap.
3. Stop Solution: 1 bottle containing 15 mL. Ready to use sulphuric acid, 0.2 mol/L; red cap.
4. Washing Solution (20x conc.)*: 1 bottle each containing 50 mL of a 20-fold concentrated buffer (pH 7.2 ± 0.2) for washing the wells; white cap.
5. Chikungunya antigen, lyophilized: 6 bottles containing lyophilized Chikungunya antigen solution; red cap
6. Chikungunya antibody Solution ****: 1 bottle containing 6 mL of biotinylated Chikungunya antibody, ready to use; coloured blue; white cap.
7. Streptavidin conjugate**: 1 bottle containing 6 mL Streptavidin conjugated with peroxidase, ready to use; coloured red; black cap.
8. TMB Substrate Solution: 1 bottle containing 15 mL 3,3',5,5'-tetramethylbenzidine (TMB); ready to use; yellow cap.
9. Chikungunya IgM High Control****: 1 bottle containing 1.5 mL; coloured yellow; ready to use; red cap.
10. Chikungunya IgM Calibrator Control****: 1 bottle containing 2 mL; coloured yellow; ready to use; green cap.
11. Chikungunya IgM Low Control***: 1 bottle containing 1.5 mL; coloured yellow; ready to use; blue cap.
* contains 0.1% Bronidox L after dilution
** contains 0.2% Bronidox L
*** contains 0.1% Kathon
**** contains 0.02% Kathon and 0.02% Bronidox L
12. 1 Strip holder
13. 1 Cover foils
14. 1 Test protocol
15. 1 distribution and identification plan
Storage
For more detailed information, please download the following document on our website.
General Description
Chikungunya virus is an arthropod borne virus of the genus Alphavirus (family Togaviridae). The Alphavirus genus contains at least 24 distinct species. These are lipid-enveloped virions with a diameter of 50 to 60 nm. Alphavirus infections are initiated by the bite of an infected mosquito, which results in the deposition of virus in subcutaneous and possibly cutaneous tissues. After an incubation period of 1 to 12 days the Chikungunya fever develops. Chikungunya fever (Chikungunya means "that which bends up", in reference to the crippling manifestations of the disease) is an acute viral infection characterized by a rapid transition from a state of good health to illness that includes severe arthralgia and fever.
The virus has major importance in Africa and Asia. From 20% to more than 90% of the population of tropical and subtropical show serologic evidence of infection. Because Aedes mosquitoes are increasingly prevalent in North Africa and South America, where the population would be uniformly susceptible to infection, the possibility for epidemics is evident. Chikungunya virus infections are imported to central Europe mainly by travellers to tropical and subtropical countries.

Citations


Have you cited DEIA2163 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Maternal and congenital infections arising from Zika, dengue and Chikungunya arboviruses in Salvador, Brazil

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

Authors: Duarte, Alan Oliveira; Oliveira, Joao Vitor; Xavier Carvalho, Tereza Cristina; Pessoa, Lorena de Brito; Magalhaes Filho, Claudio; Souza Lima, Jessica Graziele; Carvalho, Daniel Augusto; dos Santos, Daiana Carlos; Santos, Cleiton Silva; Pessoa, Rosana; Souza, Gloryane Bessa; Calcagno, Juan Ignacio; Santana, Edilene Mota; de Oliveira, Aline Sousa; de Oliveira Francisco, Marcos Vinicius Lima; Gouvea Costa, Bernardo Gratival; Gomes, Lillian Nunes; Romero, Fernando; Khouri, Ricardo; Alcantara, Luiz Carlos, Jr.; de Mendonca Lima, Fernanda Washington; de Siqueira, Isadora Cristina

Background: Salvador was one of the Brazilian cities most affected during the 2015 Zika virus (ZIKV) outbreak. Methods: A cross-sectional study was performed with enrolment of parturients and their newborns. Results: Positive IgM antibodies for ZIKV, dengue (DENV) and Chikungunya (CHIKV) were present in 6.9, 11.9 and 22.8% of the parturients, and IgG antibodies were detected in 72.3, 92.3 and 38.6%, respectively. No cases of DENV congenital infection were identified. ZIKV and CHIKV congenital infections were observed in 16.5 and 13% of newborns, respectively. Conclusions: High exposure rates to the three arboviruses and the identification of newborns with ZIKV and CHIKV congenital infections reinforces the necessity of ZIKV and CHIKV prenatal and neonatal screening in endemic regions.

Inactivation and Removal of Chikungunya Virus and Mayaro Virus from Plasma-derived Medicinal Products

VIRUSES-BASEL

Authors: Yue, Constanze; Teitz, Sebastian; Miyabashi, Tomoyuki; Boller, Klaus; Lewis-Ximenez, Lia Laura; Baylis, Sally A.; Bluemel, Johannes

Background: Chikungunya virus (CHIKV) and Mayaro virus (MAYV) are closely related members of the Semliki Forest complex within the genus alphavirus and are transmitted by arthropods, causing acute febrile illness in humans. CHIKV has spread to almost all continents, whereas autochthonous MAYV infections have been reported in South America and in the Caribbean. Nevertheless, there was concern about potential spread of MAYV to other regions similar to CHIKV in the past. The risk for transmission of emerging viruses by blood transfusion and the safety of plasma-derived medicinal products (PDMPs) are constant concerns. The manufacturing processes of PDMPs include procedures to inactivate/remove viruses. Methods: In this study, we investigated the reduction of MAYV and CHIKV by heat inactivation in various matrices, solvent/detergent treatment and nanofiltration. Results: Unexpectedly, MAYV was significantly more resistant to heat and solvent/detergent treatment compared to CHIKV. However, being similar in size, both MAYV and CHIKV were removed below the detection limit by 35 nm virus filters. Conclusions: The inactivation profiles of different alphavirus members vary considerably, even within the Semliki Forest Complex. However, robust dedicated viral inactivation/removal procedures commonly used in the plasma product industry are effective in inactivating or removing MAYV and CHIKV.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket